Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: August 3, 2015

Clarification on Expiry of Listed Options

News & Announcements 2015By PharmAust August 3, 2015

150803_Clarification on Expiry of Listed Options

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

👇👇👇

JP Equity Partners@jpequitypartner

Join @ausbiztv tomorrow at 9:20am EST / 7:20am WST to hear the Chief Scientific Officer of @PharmAust $PAA, Dr Richard Mollard deliver an update on the status of the development of the Company’s primary drug candidate, Monepantel (MPL).

Please join at: https://www.ausbiz.com.au/

Reply on Twitter 1309043218022105091 Retweet on Twitter 13090432180221050911 Like on Twitter 13090432180221050915 Twitter 1309043218022105091

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions